The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013

British Journal of Haematology

Volumn 170, Issue 6, 2015, Pages 847-858

  Olsson, Linda ^a   Ivanov Öfverholm, Ingegerd ^b   Norén Nyström, Ulrika ^c   Zachariadis, Vasilios ^b   Nordlund, Jessica ^d   Sjögren, Helene ^e   Golovleva, Irina ^c   Nordgren, Ann ^b   Paulsson, Kajsa ^a   Heyman, Mats ^b   Barbany, Gisela ^b   Johansson, Bertil ^a,f  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f Lund University   (Sweden)

Author keywords

IKZF1 deletion; P2RY8 CRLF2, minimal residual disease; Paediatric B cell precursor acute lymphoblastic leukaemia; Risk stratifying factors

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOGENETICS; ERG GENE; EVENT FREE SURVIVAL; FEMALE; GENE; GENE DELETION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; IKZF1 GENE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MINIMAL RESIDUAL DISEASE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; P2RY8 CRLF2 GENE; PAR1 GENE; PEDIATRIC B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; RECURRENCE RISK; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME; AGE; CHROMOSOME 12; CHROMOSOME 21; COHORT ANALYSIS; GENE EXPRESSION; GENE TRANSLOCATION; GENETICS; INFANT; MORTALITY; OUTCOME ASSESSMENT; PATHOLOGY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROGNOSIS; SWEDEN;

ANTINEOPLASTIC AGENT; ERG PROTEIN, HUMAN; IKAROS TRANSCRIPTION FACTOR; IKZF1 PROTEIN, HUMAN; PROTEINASE ACTIVATED RECEPTOR 1; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR REL;

ADOLESCENT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 21; COHORT STUDIES; GENE DELETION; GENE EXPRESSION; HUMANS; IKAROS TRANSCRIPTION FACTOR; INFANT; NEOPLASM, RESIDUAL; PATIENT OUTCOME ASSESSMENT; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-REL; RECEPTOR, PAR-1; SWEDEN; TRANS-ACTIVATORS; TRANSLOCATION, GENETIC;

EID: 84940582944     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13514     Document Type: Article

References (49)

1. Asai, D., Imamura, T., Suenobu, S., Saito, A., Hasegawa, D., Deguchi, T., Hashii, Y., Matsumoto, K., Kawasaki, H., Hori, H., Iguchi, A., Kosaka, Y., Kato, K., Horibe, K., Yumura-Yagi, K., Hara, J. & Oda, M. (2013) IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan. Cancer Medicine, 2, 412-419.
2. Björklund, E., Matinlauri, I., Tierens, A., Axelsson, S., Forestier, E., Jacobsson, S., Ahlberg, A.J., Kauric, G., Mäntymaa, P., Osnes, L., Penttilä, T.L., Marquart, H., Savolainen, E.R., Siitonen, S., Torikka, K., Mazur, J. & Porwit, A. (2009) Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment. Journal of Pediatric Hematology/Oncology, 31, 406-415.
3. Borowitz, M.J., Devidas, M., Hunger, S.P., Bowman, W.P., Carroll, A.J., Carroll, W.L., Linda, S., Martin, P.L., Pullen, D.J., Viswanatha, D., Willman, C.L., Winick, N. & Camitta, B.M. (2008) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood, 111, 5477-5485.
4. Brisco, M.J., Condon, J., Hughes, E., Neoh, S.-H., Nicholson, I., Sykes, P.J., Tauro, G., Ekert, H., Water, K., Toogood, I., Seshadri, R. & Morley, A. (1993) Prognostic significance of detection of monoclonality in remission marrow in acute lymphoblastic leukemia in childhood. Australian and New Zealand Children's Cancer Study Group. Leukemia, 7, 1514-1520.
5. Brüggemann, M., Schrauder, A., Raff, T., Pfeifer, H., Dworzak, M., Ottmann, O.G., Asnafi, V., Baruchel, A., Bassan, R., Benoit, Y., Biondi, A., Cavé, H., Dombret, H., Fielding, A.K., Foà, R., Gökbuget, N., Goldstone, A.H., Goulden, N., Henze, G., Hoelzer, D., Janka-Schaub, G.E., Macintyre, E.A., Pieters, R., Rambaldi, A., Ribera, J.M., Schmiegelow, K., Spinelli, O., Stary, J., von Stackelberg, A., Kneba, M., Schrappe, M. & van Dongen, J.J. (2010) Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia, 24, 521-535.
6. Cavé, H., van der Werff ten Bosch, J., Suciu, S., Guidal, C., Waterkeyn, C., Otten, J., Bakkus, M., Thielemans, K., Grandchamp, B. & Vilmer, E. (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. The New England Journal of Medicine, 339, 591-598.
7. Caye, A., Beldjord, K., Mass-Malo, K., Drunat, S., Soulier, J., Gandemer, V., Baruchel, A., Bertrand, Y., Cavé, H. & Clappier, E. (2013) Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia. Haematologica, 98, 597-601.
8. Chen, I.M., Harvey, R.C., Mullighan, C.G., Gastier-Foster, J., Wharton, W., Kang, H., Borowitz, M.J., Camitta, B.M., Carroll, A.J., Devidas, M., Pullen, D.J., Payne-Turner, D., Tasian, S.K., Reshmi, S., Cottrell, C.E., Reaman, G.H., Bowman, W.P., Carroll, W.L., Loh, M.L., Winick, N.J., Hunger, S.P. & Willman, C.L. (2012) Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood, 119, 3512-3522.
9. Clappier, E., Auclerc, M.F., Rapion, J., Bakkus, M., Caye, A., Khemiri, A., Giroux, C., Hernandez, L., Kabongo, E., Savola, S., Leblanc, T., Yakouben, K., Plat, G., Costa, V., Ferster, A., Girard, S., Fenneteau, O., Cayuela, J.M., Sigaux, F., Dastugue, N., Suciu, S., Benoit, Y., Bertrand, Y., Soulier, J. & Cavé, H. (2014) An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia, 28, 70-77.
10. Coustan-Smith, E., Sancho, J., Behm, F.G., Hancock, M.L., Razzouk, B.I., Ribeiro, R.C., Rivera, G.K., Rubnitz, J.E., Sandlund, J.T., Pui, C.H. & Campana, D. (2002) Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood, 100, 52-58.
11. Den Boer, M.L., van Slegtenhorst, M., De Menezes, R.X., Cheok, M.H., Buijs-Gladdines, J.G., Peters, S.T., Van Zutven, L.J., Beverloo, H.B., Van der Spek, P.J., Escherich, G., Horstmann, M.A., Janka-Schaub, G.E., Kamps, W.A., Evans, W.E. & Pieters, R. (2009) A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. The Lancet Oncology, 10, 125-134.
12. Dörge, P., Meissner, B., Zimmermann, M., Möricke, A., Schrauder, A., Bouquin, J.P., Schewe, D., Harbott, J., Teigler-Schlegel, A., Ratei, R., Ludwig, W.D., Koehler, R., Bartram, C.R., Schrappe, M., Stanulla, M. & Cario, G. (2013) IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica, 98, 428-432.
13. van Dongen, J.J.M., Seriu, T., Panzer-Grümayer, E.R., Biondi, A., Pongers-Willemse, M.J., Corral, L., Stolz, F., Schrappe, M., Masera, G., Kamps, W.A., Gadner, H., van Wering, E.R., Ludwig, W.D., Basso, G., de Bruijn, M.A., Cazzaniga, G., Hettinger, K., van der Does-van den Berg, A., Hop, W.C.J., Riehm, H. & Bartram, C.R. (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. The Lancet, 352, 1731-1738.
14. Dupuis, A., Gaub, M.P., Legrain, M., Drenou, B., Mauvieux, L., Lutz, P., Herbrecht, R., Chan, S. & Kastner, P. (2013) Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations. Leukemia, 27, 503-507.
15. Enshaei, A., Schwab, C.J., Konn, Z.J., Mitchell, C.D., Kinsey, S.E., Wade, R., Vora, A., Harrison, C.J. & Moorman, A.V. (2013) Long-term follow-up of ETV6-RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor. Leukemia, 27, 2256-2259.
16. Frandsen, T.L., Heyman, M., Abrahamsson, J., Vettenranta, K., Åsberg, A., Vaitkeviciene, G., Pruunsild, K., Toft, N., Birgens, H., Hallböök, H., Quist-Paulsen, P., Griškevičius, L., Helt, L., Hansen, B.V. & Schmiegelow, K. (2014) Complying with the European Clinical Trials directive while surviving the administrative pressure - an alternative approach to toxicity registration in a cancer trial. European Journal of Cancer, 50, 251-259.
17. Georgopoulos, K., Moore, D.D. & Derfler, B. (1992) Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment. Science, 258, 808-812.
18. Harvey, R.C., Mullighan, C.G., Chen, I.M., Wharton, W., Mikhail, F.M., Carroll, A.J., Kang, H., Liu, W., Dobbin, K.K., Smith, M.A., Carroll, W.L., Devidas, M., Bowman, W.P., Camitta, B.M., Reaman, G.H., Hunger, S.P., Downing, J.R. & Willman, C.L. (2010) Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood, 115, 5312-5321.
19. Kuiper, R.P., Schoenmakers, E.F., van Reijmersdal, S.V., Hehir-Kwa, J.Y., van Kessel, A.G., van Leeuwen, F.N. & Hoogerbrugge, P.M. (2007) High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia, 21, 1258-1266.
20. Kuiper, R.P., Waanders, E., van der Velden, V.H.J., van Reijmersdal, S.V., Venkatachalam, R., Scheijen, B., Sonneveld, E., van Dongen, J.J.M., Veerman, A.J.P., van Leeuwen, F.N., van Kessel, A.G. & Hoogerbrugge, P.M. (2010) IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia, 24, 1258-1264.
21. Li, A., Liu, Z., Lezon-Geyda, K., Sarkar, S., Lannin, D., Schulz, V., Krop, I., Winer, E., Harris, L. & Tuck, D. (2011) GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays. Nucleic Acids Research, 39, 4928-4941.
22. Martinelli, G., Iacobucci, I., Storlazzi, C.T., Vignetti, M., Paoloni, F., Cilloni, D., Soverini, S., Vitale, A., Chiaretti, S., Cimino, G., Papayannidis, C., Paolini, S., Elia, L., Fazi, P., Meloni, G., Amadori, S., Saglio, G., Pane, F., Baccarani, M. & Foà, R. (2009) IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. Journal of Clinical Oncology, 27, 5202-5207.
23. Meyer, C., Zur Stadt, U., Escherich, G., Hofmann, J., Binato, R., Barbosa Tda, C., Emerenciano, M., Pombo-de-Oliveira, M.S., Horstmann, M. & Marschalek, R. (2013) Refinement of IKZF1 recombination hotspots in pediatric BCP-ALL patients. American Journal of Blood Research, 3, 165-173.
24. Moorman, A.V., Enshaei, A., Schwab, C., Wade, R., Chilton, L., Elliott, A., Richardson, S., Hancock, J., Kinsey, S.E., Mitchell, C.D., Goulden, N., Vora, A. & Harrison, C.J. (2014) A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood, 124, 1434-1444.
25. Mullighan, C.G., Goorha, S., Radtke, I., Miller, C.B., Coustan-Smith, E., Dalton, J.D., Girtman, K., Mathew, S., Ma, J., Pounds, S.B., Su, X., Pui, C.H., Relling, M.V., Evans, W.E., Shurtleff, S.A. & Downing, J.R. (2007) Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature, 446, 758-764.
26. Mullighan, C.G., Su, X., Zhang, J., Radtke, I., Phillips, L.A., Miller, C.B., Ma, J., Liu, W., Cheng, C., Schulman, B.A., Harvey, R.C., Chen, I.M., Clifford, R.J., Carroll, W.L., Reaman, G., Bowman, W.P., Devidas, M., Gerhard, D.S., Yang, W., Relling, M.V., Shurtleff, S.A., Campana, D., Borowitz, M.J., Pui, C.H., Smith, M., Hunger, S.P., Willman, C.L. & Downing, J.R. (2009) Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. The New England Journal of Medicine, 360, 470-480.
27. Öfverholm, I., Tran, A.N., Heyman, M., Zachariadis, V., Nordenskjöld, M., Nordgren, A. & Barbany, G. (2013) Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols. Leukemia, 27, 1936-1939.
28. Olsson, L. & Johansson, B. (2015) Ikaros and leukaemia. British Journal of Haematology, 169, 479-491.
29. Olsson, L., Castor, A., Behrendtz, M., Biloglav, A., Forestier, E., Paulsson, K. & Johansson, B. (2014) Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011. Leukemia, 28, 302-310.
30. Olsson, L., Albitar, F., Castor, A., Behrendtz, M., Biloglav, A., Paulsson, K. & Johansson, B. (2015) Cooperative genetic changes in pediatric B-cell precursor acute lymphoblastic leukemia with deletions or mutations of IKZF1. Genes, Chromosomes & Cancer, 54, 315-325.
31. Palmi, C., Vendramini, E., Silvestri, D., Longinotti, G., Frison, D., Cario, G., Shochat, C., Stanulla, M., Rossi, V., Di Meglio, A.M., Villa, T., Giarin, E., Fazio, G., Leszl, A., Schrappe, M., Basso, G., Biondi, A., Izraeli, S., Conter, V., Valsecchi, M.G., Cazzaniga, G. & Te Kronnie, G. (2012) Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia, 26, 2245-2253.
32. Palmi, C., Valsecchi, M.G., Longinotti, G., Silvestri, D., Carrino, V., Conter, V., Basso, G., Biondi, A., Kronnie, G.T. & Cazzaniga, G. (2013) What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia? Haematologica, 98, 1226-1231.
33. Pui, C.H., Carroll, W.L., Meshinchi, S. & Arceci, R.J. (2011) Biology, risk stratification, and therapy of pediatric acute leukemias: an update. Journal of Clinical Oncology, 29, 551-565.
34. Qazi, S. & Uckun, F.M. (2013) Incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia. Haematologica, 98, e151-e152.
35. Qazi, S., Ma, H. & Uckun, F.M. (2013) Absence of genomic Ikaros/IKZF1 deletions in pediatric B-precursor acute lymphoblastic leukemia. International Journal of Molecular Medical Science, 3, 72-82.
36. Schmiegelow, K., Forestier, E., Hellebostad, M., Heyman, M., Kristinsson, J., Söderhäll, S. & Taskinen, M. (2010) Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukaemia. Leukemia, 24, 345-354.
37. Schwab, C.J., Jones, L.R., Morrison, H., Ryan, S.L., Yigittop, H., Schouten, J.P. & Harrison, C.J. (2010) Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. Genes, Chromosomes & Cancer, 49, 1104-1113.
38. Schwab, C.J., Chilton, L., Morrison, H., Jones, L., Al-Shehhi, H., Erhorn, A., Russell, L.J., Moorman, A.V. & Harrison, C.J. (2013) Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features. Haematologica, 98, 1081-1088.
39. Toft, N., Birgens, H., Abrahamsson, J., Bernell, P., Griškevičius, L., Hallböök, H., Heyman, M., Holm, M.S., Hulegårdh, E., Klausen, T.W., Marquart, H.V., Jónsson, O.G., Nielsen, O.J., Quist-Paulsen, P., Taskinen, M., Vaitkeviciene, G., Vettenranta, K., Åsberg, A. & Schmiegelow, K. (2013) Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. European Journal of Haematology, 90, 404-412.
40. Uckun, F.M., Ma, H., Ishkhanian, R., Arellano, M., Shahidzadeh, A., Termuhlen, A., Gaynon, P.S. & Qazi, S. (2013) Constitutive function of the Ikaros transcription factor in primary leukemia cells from pediatric newly diagnosed high-risk and relapsed B-precursor ALL patients. PLoS ONE, 8, e80732.
41. van der Veer, A., Waanders, E., Pieters, R., Willemse, M.E., Van Reijmersdal, S.V., Russell, L.J., Harrison, C.J., Evans, W.E., van der Velden, V.H.J., Hoogerbrugge, P.M., Van Leeuwen, F., Escherich, G., Horstmann, M.A., Mohammadi Khankahdani, L., Rizopoulos, D., De Groot-Kruseman, H.A., Sonneveld, E., Kuiper, R.P. & Den Boer, M.L. (2013) Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood, 122, 2622-2629.
42. van der Veer, A., Zaliova, M., Mottadelli, F., De Lorenzo, P., Te Kronnie, G., Harrison, C.J., Cavé, H., Trka, J., Saha, V., Schrappe, M., Pieters, R., Biondi, A., Valsecchi, M.G., Stanulla, M., den Boer, M.L. & Cazzaniga, G. (2014) IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood, 123, 1691-1698.
43. Volejnikova, J., Mejstrikova, E., Dörge, P., Meissner, B., Zimmermannova, O., Svojgr, K., Stanulla, M., Cario, G., Schrappe, M., Stary, J., Hrusak, O., Trka, J. & Fronkova, E. (2013) Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia. Pediatric Blood & Cancer, 60, 420-427.
44. Vora, A., Goulden, N., Wade, R., Mitchell, C., Hancock, J., Hough, R., Rowntree, C. & Richards, S. (2013) Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. The Lancet Oncology, 14, 199-209.
45. Waanders, E., van der Velden, V.H.J., van der Schoot, C.E., van Leeuwen, F.N., van Reijmersdal, S.V., de Haas, V., Veerman, A.J., van Kessel, A.G., Hoogerbrugge, P.M., Kuiper, R.P. & van Dongen, J.J.M. (2011) Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia, 25, 254-258.
46. Yamaji, K., Okamoto, T., Yokota, S., Watanabe, A., Horikoshi, Y., Asami, K., Kikuta, A., Hyakuna, N., Saikawa, Y., Ueyama, J., Watanabe, T., Okada, M., Taga, T., Kanegane, H., Kogawa, K., Chin, M., Iwai, A., Matsushita, T., Shimomura, Y., Hori, T. & Tsurusawa, M. (2010) Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. Pediatric Blood & Cancer, 55, 1287-1295.
47. Yamashita, Y., Shimada, A., Yamada, T., Yamaji, K., Hori, T., Tsurusawa, M., Watanabe, A., Kikuta, A., Asami, K., Saito, A.M. & Horibe, K. (2013) IKZF1 and CRLF2 gene alterations correlate with poor prognosis in Japanese BCR-ABL1-negative high-risk B-cell precursor acute lymphoblastic leukemia. Pediatric Blood & Cancer, 60, 1587-1592.
48. Yang, J.J., Bhojwani, D., Yang, W., Cai, X., Stocco, G., Crews, K., Wang, J., Morrison, D., Devidas, M., Hunger, S.P., Willman, C.L., Raetz, E.A., Pui, C.H., Evans, W.E., Relling, M.V. & Carroll, W.L. (2008) Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood, 112, 4178-4183.
49. Zaliova, M., Zimmermannova, O., Dörge, P., Eckert, C., Möricke, A., Zimmermann, M., Stuchly, J., Teigler-Schlegel, A., Meissner, B., Koehler, R., Bartram, C.R., Karawajew, L., Rhein, P., Zuna, J., Schrappe, M., Cario, G. & Stanulla, M. (2014) ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia. Leukemia, 28, 182-185.